# TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

> **NCT02396511** · PHASE2 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 2 (actual)

## Conditions studied

- Choriocarcinoma

## Interventions

- **BIOLOGICAL:** TRC105
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT02396511
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396511, "TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02396511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*